TY - JOUR
T1 - Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System
AU - Frei, Chris
AU - Le, Hannah
AU - McHugh, Daniel
AU - Ryan, Kellie
AU - Jones, Xavier
AU - Galley, Samantha
AU - Franklin, Kathleen
AU - Baus, Courtney J.
AU - Tavera, Juan
AU - Janania-Martinez, Michelle
AU - Gregorio, David
AU - Ananth, Snegha
AU - Uribe, Ricardo
AU - Surapaneni, Prathibha
AU - Espinoza-Gutarra, Manuel
AU - Song, Michael M.
AU - Teng, Chengwen
AU - Obodozie-Ofoegbu, Obiageri O.
AU - Nooruddin, Zohra
N1 - Funding Information:
for the study was provided by AstraZeneca as a research grant to the Foundation for Advancing Veterans’ Health Research, a non-profit entity within the Audie L. Murphy Veterans Hospital, San Antonio, TX. Dr. Frei was supported, in part, by an NIH Clinical and Translational Science Award (National Center for Advancing Translational Sciences, UL1 TR002645) while the study was being conducted. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the National Institutes of Health, or the authors’ affiliated institutions. The study authors would like to thank Alyssa C. Eaves (student pharmacist at the UT Austin College of Pharmacy) for her creative adaptation of the study enrollment figure.
Funding Information:
This study was funded by AstraZeneca.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.
AB - The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.
KW - adverse events
KW - chart review
KW - Chronic lymphocytic leukemia
KW - discontinuation
KW - dose reduction
KW - novel agents
UR - http://www.scopus.com/inward/record.url?scp=85100842857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100842857&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1876863
DO - 10.1080/10428194.2021.1876863
M3 - Article
C2 - 33569992
AN - SCOPUS:85100842857
VL - 62
SP - 1664
EP - 1673
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 7
ER -